Teva Pharmaceutical Industries Limited
TEVA
$12.78
-$0.40-3.04%
| Weiss Ratings | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.29 | |||
| Price History | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 6.03% | |||
| 60-Day Total Return | 27.46% | |||
| 90-Day Total Return | 41.65% | |||
| Year to Date Total Return | 33.55% | |||
| 1-Year Total Return | 67.65% | |||
| 2-Year Total Return | 40.95% | |||
| 3-Year Total Return | 32.56% | |||
| 5-Year Total Return | -3.00% | |||
| 52-Week High % Change | -8.54% | |||
| 52-Week Low % Change | 86.73% | |||
| Price | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $14.47 | |||
| 52-Week Low Price | $7.09 | |||
| 52-Week Low Price (Date) | May 31, 2023 | |||
| 52-Week High Price (Date) | Apr 08, 2024 | |||
| Valuation | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 14.91B | |||
| Enterprise Value | 32.58B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.51 | |||
| Earnings Per Share Growth | -76.86% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.95 | |||
| Price/Book (Q) | 1.99 | |||
| Enterprise Value/Revenue (TTM) | 2.05 | |||
| Price | $14.25 | |||
| Enterprise Value/EBITDA (TTM) | 7.50 | |||
| Enterprise Value/EBIT | 10.22 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.14B | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | $0.07 | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | $0.07 | |||
| Company Info | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 972 3 914 8213 | |||
| Address | -- | |||
| Website | www.tevapharm.com | |||
| Country | Israel | |||
| Year Founded | 1901 | |||
| Profitability | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 20.06% | |||
| Profit Margin | -3.52% | |||
| Management Effectiveness | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 4.54% | |||
| Return on Equity | -- | |||
| Income Statement | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 15.85B | |||
| Total Revenue (TTM) | 15.85B | |||
| Revenue Per Share | $13.94 | |||
| Gross Profit (TTM) | 7.65B | |||
| EBITDA (TTM) | 4.33B | |||
| EBIT (TTM) | 3.18B | |||
| Net Income (TTM) | -559.00M | |||
| Net Income Avl. to Common (TTM) | -559.00M | |||
| Total Revenue Growth (Q YOY) | 14.75% | |||
| Earnings Growth (Q YOY) | 132.17% | |||
| EPS Diluted (TTM) | -0.51 | |||
| EPS Diluted Growth (Q YOY) | 131.62% | |||
| Balance Sheet | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 3.23B | |||
| Cash Per Share (Q) | $2.84 | |||
| Total Current Assets (Q) | 12.49B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 8.13B | |||
| Current Ratio (Q) | 1.019 | |||
| Book Value Per Share (Q) | $6.70 | |||
| Total Assets (Q) | 43.48B | |||
| Total Current Liabilities (Q) | 12.25B | |||
| Total Debt (Q) | 20.27B | |||
| Total Liabilities (Q) | 35.35B | |||
| Total Common Equity (Q) | 7.51B | |||
| Cash Flow | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 968.00M | |||
| Cash from Financing (TTM) | -1.91B | |||
| Net Change in Cash (TTM) | 393.00M | |||
| Levered Free Cash Flow (TTM) | 3.28B | |||
| Cash from Operations (TTM) | 1.37B | |||
